HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mascaró, C. Articles by Haro, D. Search for Related Content PubMed PubMed Citation Articles by Mascaró, C. Articles by Haro, D. Social Bookmarking                      What's this?

J Biol Chem, Vol. 273, Issue 15, 8560-8563, April 10, 1998

Control of Human Muscle-type Carnitine Palmitoyltransferase I Gene Transcription by Peroxisome Proliferator-activated Receptor^*

Cristina Mascaró, Elena Acosta, José A. Ortiz, Pedro F. Marrero, Fausto G. Hegardt, and Diego Haro^§

From the Unit of Biochemistry, School of Pharmacy, University of Barcelona, 08028 Barcelona, Spain

	ABSTRACT

Top Abstract Introduction Procedures Results & Discussion References

The expression of several genes involved in intra- and extracellular lipid metabolism, notably those involved in peroxisomal and mitochondrial -oxidation, is mediated by ligand-activated receptors, collectively referred to as peroxisome proliferator-activated receptors (PPARs). To gain more insight into the control of expression of carnitine palmitoyltransferase (CPT) genes, which are regulated by fatty acids, we have examined the transcriptional regulation of the human MCPT I gene. We have cloned by polymerase chain reaction the 5'-flanking region of this gene and demonstrated its transcriptional activity by transfection experiments with the CAT gene as a reporter. We have also shown that this is a target gene for the action of PPARs, and we have localized a PPAR responsive element upstream of the first exon. These results show that PPAR regulates the entry of fatty acids into the mitochondria, which is a crucial step in their metabolism, especially in tissues like heart, skeletal muscle and brown adipose tissue in which fatty acids are a major source of energy.

	INTRODUCTION

Top Abstract Introduction Procedures Results & Discussion References

The incorporation of activated long-chain fatty acids into the mitochondria to be catabolized through -oxidation is produced by the mitochondrial carnitine palmitoyltransferase (CPT)¹ enzyme system. CPT I, the outer membrane component of this system, is the main control point in the -oxidation pathway. CPT I is thus a suitable site for pharmacological control of fatty acid oxidation in conditions such as diabetes or heart diseases.

Two isoforms of CPT I have been described, which have been designated LCPT I and MCPT I since these isoforms are mainly expressed in liver and muscle respectively. The MCPT I gene is expressed not only in skeletal muscle but also in heart and brown and white adipose tissue (1-4). This expression pattern may be of great significance since fatty acids are a major source of energy for heart, skeletal muscle, and brown adipose tissue.

The CPT I gene expression is regulated by fatty acids and peroxisome proliferators (5, 6). To gain more insight into the control of CPT I gene expression by fatty acids, we have examined the transcriptional regulation of CPT I genes. The expression of several genes involved in intra- and extracellular lipid metabolism, notably those involved in peroxisomal and mitochondrial -oxidation, is mediated by ligand-activated receptors collectively referred to as peroxisome proliferator-activated receptors (PPARs); these receptors are members of the nuclear receptor superfamily. PPARs are activated by a wide array of peroxisome proliferators and also by natural and synthetic fatty acids (7, 8), antidiabetic drugs (9, 10), prostaglandin J₂ (10), and leukotriene B₄ (11).

We have amplified by polymerase chain reaction (PCR) the 5' region of the human heart and brown adipose tissue CPT I gene and demonstrate, first, the transcriptional activity of this fragment and, second, the presence of a PPRE in the 5'-flanking region of this gene. In CV1 cells, the activation of the CPT I gene by PPAR was dependent on the addition of exogenous ligands.

	EXPERIMENTAL PROCEDURES

Top Abstract Introduction Procedures Results & Discussion References

Plasmids-- pCPTCAT, containing an 882-base pair fragment of the human MCPT I gene, was constructed by the application of the PCR using a pair of oligonucleotide primers, CPTF (5'-CCTGGCTGCAGCTTAGAATAA) and CPTR (5'-GGAGTTGATCCCAGACAGG TAGAC), corresponding to coordinates 909 to 889 and +126 to +92, respectively, of the human MCPT I gene (12) and human genomic DNA as a template. The PstI-AvrII-digested PCR product was cloned into the PstI-XbaI sites of chloramphenicol acetyltransferase (CAT) vector pCAT-BASIC reporter gene (Promega). To confirm the sequence, the PCR-amplified fragment was automatically sequenced using the fluorescent terminator kit (Perkin-Elmer).

Heterologous promoter plasmids were constructed in the herpesvirus thymidine kinase gene promoter upstream of the CAT reporter gene pBLCAT2 (13). pTKCATCPT contains a fragment corresponding to coordinates 774 to 755 of the mitochondrial HMG-CoA synthase gene. It was constructed by cloning the oligonucleotide 5'-agctTGACCTTTTCCCTACATTTG annealed to 5'-tcgaCAAATGTAGGGAAAAGGTCA into pBLCAT2 (nucleotides designated in lowercase were added to provide cohesive HindIII-SalI ends at the 5' and 3' termini, respectively). The insert in this plasmid had the same 5'  3' orientation as found in the human MCPT I gene promoter. DNA sequence analysis, by the fluorescent terminator kit was performed to confirm insert orientation.

Cell Culture and Transfections-- CV1 cells were cultured in minimal essential media supplemented with 10% fetal calf serum. Cells were typically cotransfected with 10 µg of the reporter MCPT I-CAT gene construct and, when indicated, with 1 µg of effector plasmids expressing full-length cDNAs for mouse PPAR, PPAR2, or PPAR. 4 µg of plasmid pRSVGAL (Rous sarcoma virus promoter -galactosidase) was included as internal control in cotransfections. Transfection experiments were carried out by the calcium-phosphate method as described (14, 15). After removal of the calcium-phosphate-DNA precipitate, cells were re-fed with medium supplemented with 10% delipidated calf serum. Experiments with ligand included either vehicle (dimethyl sulfoxide or ethyl alcohol) or ligand (10 µM PGJ2 (15-deoxy-^12,14-prostaglandin J2), 30 µM LY-171883, or 30 µM linoleic acid). All ligands used were from Sigma. Cells were harvested 48 h after re-feeding.

-Galactosidase and CAT Assays-- Extracts of harvested cells were prepared by liquid nitrogen freeze/thaw disruption (three times) after resuspension in 100 µl of 0.25 M Tris-HCl, pH 7.5. -Galactosidase activity was determined (15) in a 10-20-µl volume of extract to normalize for transfection efficiency. All samples assayed for CAT activity were first incubated at 65 °C for 5 min. CAT assays were performed (14) for 60 min. Radioactivity of samples was measured on an LKB-1217 liquid scintillation counter.

Transcription/Translation in Vitro-- cDNAs for the receptors (mouse PPAR, PPAR2, PPAR, and human RXR) were transcribed and translated by using a commercially available kit according to the instructions of the manufacturer (Promega).

Electrophoretic Mobility Shift Analysis-- 2 µl of mPPAR, mPPAR, and mPPAR with or without hRXR (2 µl) synthesized in vitro were preincubated on ice for 10 min in 10 mM Tris-HCl, pH 8.0, 40 mM KCl, 0.05% (v/v) Nonidet P-40, 6% glycerol, 1 mM dithiothreitol, and 2 µg of poly(dI-dC). The total amount of reticulocyte lysate was kept constant in each reaction (4 µl) by the addition of unprogrammed lysate. For competition experiments, a 25-100-fold molar excess of MCPT I PPRE or MCPT I MPPRE double-stranded probes, relative to the labeled probe, was included during preincubation. MCPT I PPRE is the fragment corresponding to coordinates 774 to 755 of the MCPT I gene, which was used to prepare pTKCATCPT. MCPT I MPPRE is the fragment corresponding to coordinates 782 to 748 of the MCPT I gene, but the nucleotides corresponding to the PPAR binding sequence have been mutated (CACATCGGTGACCctcgagggatccTTGGCTATTT, nucleotides described in lowercase correspond to those that have been changed from the wild type sequence). Next, 2 ng of MCPT I PPRE, ³²P-labeled by fill-in with Klenow polymerase, was added, and the incubation was continued for 15 min at room temperature. The final volume for all reactions was 20 µl. Samples were electrophoresed at 4 °C on a 4.5% polyacrylamide gel in 0.5× TBE buffer (45 mM Tris, 45 mM boric acid, 1 mM EDTA, pH 8.0).

	RESULTS AND DISCUSSION

Top Abstract Introduction Procedures Results & Discussion References

The Human MCPT I Gene 5'-Flanking Region Contains a Consensus PPRE-- PPAR , , and  bind to the MCPT I PPRE as heterodimers with RXR. To elucidate the control of CPT I gene expression by fatty acids, we have examined the transcriptional regulation of CPT I genes. A BLAST search performed using the NCBI BLAST WWW Server revealed that the sequence for the human muscle type CPT I gene was included in the sequence of a BAC clone containing a part of the q arm of chromosome 22 (GenBank^TM accession number U62317). The analysis of the 5'-flanking region of this gene by the TFSEARCH routine, performed using the Kyoto Center's GenomeNet WWW Server, shows the presence of a putative PPAR binding sequence upstream of exon 1A. The comparison of this sequence with the consensus sequence required for the binding of the PPAR-RXR heterodimer, as proposed by Palmer et al. (16), shows the coincidence of 17 out of 20 bases (Fig. 1). We performed gel mobility shift assays to analyze whether PPAR-RXR heterodimers bind to the putative PPAR binding sequence of the human muscle type CPT I gene. As can be seen in Fig. 2 neither PPARs nor RXR alone binds significantly to this sequence. However, incubation of this probe with a mixture of PPAR (, , or ) and RXR resulted in a prominent complex. An oligonucleotide containing a mutated PPRE was not able to compete with the wild-type probe for the formation of the complex. The binding of the three subtypes of PPAR to the MCPT I PPRE is as strong as the binding to the mitochondrial HMG-CoA synthase PPRE, which allows the formation of the strongest complexes for all PPAR subtypes (17) (data not shown).

View larger version (15K): [in this window] [in a new window]   Fig. 1.   A, scheme of the 5'-flanking region of the human MCPT I. Indicated (open rectangles) are the positions of exons 1A, 1B, and 2 containing the translation initiation codon and the presence of the PPRE (screened box). B, comparison of the sequence of the proposed PPRE with the consensus (CONS).

View larger version (24K): [in this window] [in a new window]   Fig. 2.   Electrophoretic mobility shift assay of the muscle CPT I PPRE with PPAR-RXR heterodimers. PPAR , , and  and RXR were translated in vitro, incubated with the proposed CPT I PPRE labeled probe, and analyzed by electrophoretic mobility shift assay. Additions were as indicated on the top of the figure. Shown in panel B is a competition of the complex PPAR-RXR-PPRE with a 25-100-fold molar excess of two different unlabeled oligonucleotides: MCPT I PPRE, containing the proposed PPRE, or MCPT I MPPRE, with the proposed PPRE mutated. All isoforms of PPAR are identically competed (data not shown).

CAT Constructs Containing the 5'-Flanking Region of the MCPT I Are Activated by PPAR-- To investigate the effect of the observed binding of PPAR to the human MCPT I gene promoter on its transcriptional activity, we made constructs in which the 5'-flanking region of this gene was linked to a promoter-less bacterial CAT gene. These plasmids were introduced into cultured CV1 cells by the calcium-phosphate method, with or without an expression vector for PPARs, together with a plasmid that contains the -galactosidase coding region driven by the SV40 promoter as a control of the efficiency of the transfection. Following transfection, cells were incubated in the presence or absence of a PPAR activator, and after 48 h, the cells were harvested and CAT activity measured.

As can be seen in Fig. 3 cotransfection of PPAR expression vectors lead to a marked increase in CAT activity in the presence of the PPAR activators. Surprisingly, even though PPAR is able to bind the MCPT I PPRE in vitro, it does not activate the expression of the chimeric gene even in the presence of linoleic acid as activator.

View larger version (47K): [in this window] [in a new window]   Fig. 3.   PPAR- and -dependent activation of the human MCPT I. pCPTCAT was cotransfected with expresion vectors for PPAR, , and  into CV1 cells either in the absence or presence of LY, PGJ2, or linoleic acid, respectively as activators of the different isoforms of PPAR. Average values of -galactosidase-normalized CAT activity (means ± S.D.), from three independent transfections with two plates each, are expressed as -fold induction relative to the activity in the absence of both PPARs and activators.

The Human MCPT I PPRE Confers PPAR Responsiveness to Thymidine Kinase Gene Promoter-- Next a pair of oligonucleotides containing the human MCPT I PPRE were inserted into pBLCAT2, a plasmid containing the CAT gene under the control of the thymidine kinase gene promoter. As can be seen in Fig. 4, this sequence conferred PPAR responsiveness to the otherwise unresponsive thymidine kinase gene promoter. The results demonstrate that this human MCPT I element is able to confer PPAR and  responsiveness both on its natural context and on a normally unresponsive promoter.

View larger version (47K): [in this window] [in a new window]   Fig. 4.   The MCPT I PPRE confers PPAR responsiveness to thymidine kinase gene promoter. CV1 cells were cotransfected with the expression vector for mPPAR, mPPAR2, and PPAR and a reporter plasmid containing the CAT gene under the control of TK gene promoter and with a fragment from the 5' region of the MCPT I containing the proposed PPRE. Average values of -galactosidase-normalized CAT activity (means ± S.D.), from three independent transfections with two plates each, are expressed as -fold induction relative to the activity in the absence of expression vectors and activators.

Our data provide evidence that extends the influence of PPARs in the regulation of mitochondrial fatty acid metabolism. They influence not only activation, through the control of acyl-CoA synthetase (18), -oxidation, through medium-chain acyl-CoA dehydrogenase (19), and ketogenesis, through mitochondrial HMG-CoA synthase (20), but also, mitochondrial import through CPT I (Fig. 5). These results also support the suggestion that in higher organisms, as well as in bacteria and yeast, there is metabolic control of gene expression.

View larger version (17K): [in this window] [in a new window]   Fig. 5.   PPAR-mediated fatty acid control of mitochondrial fatty acid metabolism. FFA, free fatty acid; ACS, acyl-CoA synthetase; MCAD, medium-chain acyl-CoA dehydrogenase.

Non-insulin-dependent diabetes mellitus (NIDDM) affects between 5 and 20% of the population in Western industrialized societies (21), but despite decades of research, the pathogenesis of NIDDM remains incompletely understood. It has recently been suggested that NIDDM may have more to do with abnormalities in fat than in carbohydrate metabolism (22). There is evidence that free fatty acids are an important link between obesity and insulin resistance and NIDDM (reviewed in Ref. 23). There is also evidence that the antidiabetic action of the thiazolidinediones (insulin sensitizers that significantly reduce glucose, lipid, and insulin levels in animal models of NIDDM and obesity) are directly mediated through binding to PPAR and the resulting active conformation of the receptor (24), whose expression is high in the skeletal muscle of obese and type II diabetic subjects (25). Our hypothesis is that the transcriptional control of the muscle type CPT I gene produced by thiazolidinedione-activated PPAR may contribute to the antidiabetic effect of these agents by controlling glucose utilization in skeletal muscle through modulation of fatty acids catabolism in such cells, and studies to examine this hypothesis are now under way.

	ACKNOWLEDGEMENTS

We are indebted to Drs. Ronald M. Evans, Stephen Green, and Bruce M. Spiegelman for supplying the expression vectors for RXR and PPAR, PPAR, and PPAR, respectively. We are also grateful to Robin Rycroft of the Language Service, University of Barcelona, for valuable assistance in the preparation of the English manuscript.

	FOOTNOTES

^* This research was supported by Grant PB94-0840 from Dirección General de Investigación Científica y Técnica.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Present address: IGBMC, CNRS INSERM, Université Louis Pasteur, C.U. de Strasbourg 67404, France.

^§ To whom correspondence should be addressed: Unitat de Bioquímica, Facultat de Farmàcia, Avda. Diagonal, 643, 08028 Barcelona, Spain. Tel.: 34-3-402 45 23; Fax: 34-3-402 18 96.

¹ The abbreviations used are: CPT, carnitine palmitoyltransferase; CAT, chloramphenicol acetyltransferase; PPAR, peroxisome proliferator-activated receptor; PPRE, peroxisome proliferator-responsive element; RXR, retinoid X receptor; PCR, polymerase chain reaction; hRXR, human 9-cis-retinoic acid receptor ; TK, thymidine kinase; NIDDM, non-insulin-dependent diabetes mellitus; HMG-CoA, 3-hydroxy-3-methylglutaryl-CoA.

	REFERENCES

Top Abstract Introduction Procedures Results & Discussion References

1. Weiss, B. C., Esser, V., Foster, D. W., and McGarry, J. D. (1994) J. Biol. Chem. 269, 18712-18715[Abstract/Free Full Text]
2. Yamazaki, N., Shinohara, Y., Shima, A., and Terada, H. (1995) FEBS Lett. 363, 41-45[CrossRef][Medline] [Order article via Infotrieve]
3. Yamazaki, N., Shinohara, Y., Shima, A., Yamanaka, Y., and Terada, H. (1996) Biochim. Biophys. Acta 1307, 157-161[Medline] [Order article via Infotrieve]
4. Esser, V., Brown, N. F., Cowan, A. T., Foster, D. W., and McGarry, J. D. (1996) J. Biol. Chem. 271, 6972-6977[Abstract/Free Full Text]
5. Asins, G., Serra, D., and Hegardt, F. G. (1994) Biochem. Pharmacol. 47, 1373-1379[CrossRef][Medline] [Order article via Infotrieve]
6. Chatelain, F., Kohl, C., Esser, V., McGarry, J. D., Girard, J., and Pegorier, J. P. (1996) Eur. J. Biochem. 235, 789-798[Medline] [Order article via Infotrieve]
7. Forman, B. M., Chen, J., and Evans, R. M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4312-4317[Abstract/Free Full Text]
8. Kliewer, S. A., Sundseth, S. S., Jones, S. A., Broen, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., and Lehmann, J. M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4318-4323[Abstract/Free Full Text]
9. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkinson, W. O., Willson, T. M., and Kliewer, S. A. (1995) J. Biol. Chem. 270, 12953-12956[Abstract/Free Full Text]
10. Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., and Evans, R. (1995) Cell 83, 803-812[CrossRef][Medline] [Order article via Infotrieve]
11. Devchand, P. R., Keller, H., Peters, J. M., Vázquez, M., Gonzalez, F. J., and Wahli, W. (1996) Nature 384, 39-43[CrossRef][Medline] [Order article via Infotrieve]
12. Yamazaki, N., Yamanka, Y., Hashimoto, Y., Shinohara, Y., Shima, A., and Terada, H. (1997) FEBS Lett. 409, 401-406[CrossRef][Medline] [Order article via Infotrieve]
13. Luckow, B., and Schütz, G. (1987) Nucleic Acids Res. 15, 5490[Free Full Text]
14. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1987) Current Protocols in Molecular Biology, pp. 9.1.4-9.1.6, Green Publishing Associates/Wiley-Interscience, New York
15. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., pp. 16.66-16.67, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
16. Palmer, C. N. A., Hsu, M-H., Griffin, K. J., and Johnson, E. F. (1995) J. Biol. Chem. 270, 16114-16121[Abstract/Free Full Text]
17. Juge-Aubry, C., Pernin, A., Favez, T., Burger, A. G., Wahli, W., Meier, C. A., and Desvergne, B. (1997) J. Biol. Chem. 272, 25252-25259[Abstract/Free Full Text]
18. Schoonjans, K., Watanabe, M., Suzuki, H., Mahfoudi, A., Krey, G., Wahli, W., Grimaldi, P., Staels, B., Yamamoto, T., and Auwerx, J. (1995) J. Biol. Chem. 270, 19269-19276[Abstract/Free Full Text]
19. Gulick, T., Cresce, S., Caira, T., Moore, D. D., and Kelly, D. P. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 11012-11016[Abstract/Free Full Text]
20. Rodríguez, J. C., Gil-Gómez, G., Hegardt, F. G., and Haro, D. (1994) J. Biol. Chem. 269, 18767-18772[Abstract/Free Full Text]
21. Harris, M. I. (1989) Diabetes Care 12, 464-474[Abstract]
22. McGarry, J. D. (1992) Science 258, 766-770[Abstract/Free Full Text]
23. Boden, G. (1997) Diabetes 46, 3-10[Abstract]
24. Berger, J., Bailey, P., Biswas, C., Cullinan, C. A., Doebber, T. W., Hayes, N. S., Saperstein, R., Smith, R. G., and Leibowitz, M. D. (1996) Endocrinology 137, 4189-4195[Abstract]
25. Park, K. S., Ciaraldi, T. P., Abrams-Carter, L., Mudaliar, S., Nikoulina, S. E., and Henry, R. R. (1997) Diabetes 46, 1230-1234[Abstract]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				E. Rigamonti, G. Chinetti-Gbaguidi, and B. Staels Regulation of Macrophage Functions by PPAR-{alpha}, PPAR-{gamma}, and LXRs in Mice and Men Arterioscler. Thromb. Vasc. Biol., June 1, 2008; 28(6): 1050 - 1059. [Abstract] [Full Text] [PDF]

				T. Coll, E. Eyre, R. Rodriguez-Calvo, X. Palomer, R. M. Sanchez, M. Merlos, J. C. Laguna, and M. Vazquez-Carrera Oleate Reverses Palmitate-induced Insulin Resistance and Inflammation in Skeletal Muscle Cells J. Biol. Chem., April 25, 2008; 283(17): 11107 - 11116. [Abstract] [Full Text] [PDF]

				S. Kourimate, C. Le May, C. Langhi, A. L. Jarnoux, K. Ouguerram, Y. Zair, P. Nguyen, M. Krempf, B. Cariou, and P. Costet Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9 J. Biol. Chem., April 11, 2008; 283(15): 9666 - 9673. [Abstract] [Full Text] [PDF]

				P. Garcia-Roves, J. M. Huss, D.-H. Han, C. R. Hancock, E. Iglesias-Gutierrez, M. Chen, and J. O. Holloszy Raising plasma fatty acid concentration induces increased biogenesis of mitochondria in skeletal muscle PNAS, June 19, 2007; 104(25): 10709 - 10713. [Abstract] [Full Text] [PDF]

				M. Okada, Y. Inoue, M. Ube, F. Sano, I. Ikeda, J. Sugimoto, and S. Takagi Skeletal Muscle Susceptibility to Clofibrate Induction of Lesions in Rats Toxicol Pathol, June 1, 2007; 35(4): 517 - 520. [Abstract] [Full Text] [PDF]

				P. Lyvers Peffer, X. Lin, S. K. Jacobi, L. A. Gatlin, J. Woodworth, and J. Odle Ontogeny of Carnitine Palmitoyltransferase I Activity, Carnitine-Km, and mRNA Abundance in Pigs throughout Growth and Development J. Nutr., April 1, 2007; 137(4): 898 - 903. [Abstract] [Full Text] [PDF]

				D. Freyssenet Energy sensing and regulation of gene expression in skeletal muscle J Appl Physiol, February 1, 2007; 102(2): 529 - 540. [Abstract] [Full Text] [PDF]

				T. Degenhardt, M. Matilainen, K.-H. Herzig, T. W. Dunlop, and C. Carlberg The Insulin-like Growth Factor-binding Protein 1 Gene Is a Primary Target of Peroxisome Proliferator-activated Receptors J. Biol. Chem., December 22, 2006; 281(51): 39607 - 39619. [Abstract] [Full Text] [PDF]

				L. Michalik, J. Auwerx, J. P. Berger, V. K. Chatterjee, C. K. Glass, F. J. Gonzalez, P. A. Grimaldi, T. Kadowaki, M. A. Lazar, S. O'Rahilly, et al. International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors Pharmacol. Rev., December 1, 2006; 58(4): 726 - 741. [Abstract] [Full Text] [PDF]

				J. Mercader, J. Ribot, I. Murano, F. Felipe, S. Cinti, M. L. Bonet, and A. Palou Remodeling of White Adipose Tissue after Retinoic Acid Administration in Mice Endocrinology, November 1, 2006; 147(11): 5325 - 5332. [Abstract] [Full Text] [PDF]

				V. Y. Ng, C. Morisseau, J. R. Falck, B. D. Hammock, and D. L. Kroetz Inhibition of Smooth Muscle Proliferation by Urea-Based Alkanoic Acids via Peroxisome Proliferator-Activated Receptor {alpha}-Dependent Repression of Cyclin D1 Arterioscler. Thromb. Vasc. Biol., November 1, 2006; 26(11): 2462 - 2468. [Abstract] [Full Text] [PDF]

				D. L. Waitzberg, R. S. Torrinhas, and T. M. Jacintho New Parenteral Lipid Emulsions for Clinical Use JPEN J Parenter Enteral Nutr, July 1, 2006; 30(4): 351 - 367. [Abstract] [Full Text] [PDF]

				F. Blaschke, Y. Takata, E. Caglayan, R. E. Law, and W. A. Hsueh Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 28 - 40. [Abstract] [Full Text] [PDF]

				A. E. Civitarese, M. K. C. Hesselink, A. P. Russell, E. Ravussin, and P. Schrauwen Glucose ingestion during exercise blunts exercise-induced gene expression of skeletal muscle fat oxidative genes Am J Physiol Endocrinol Metab, December 1, 2005; 289(6): E1023 - E1029. [Abstract] [Full Text] [PDF]

				Y. Weng, C. C. DiRusso, A. A. Reilly, P. N. Black, and X. Ding Hepatic Gene Expression Changes in Mouse Models with Liver-specific Deletion or Global Suppression of the NADPH-Cytochrome P450 Reductase Gene: MECHANISTIC IMPLICATIONS FOR THE REGULATION OF MICROSOMAL CYTOCHROME P450 AND THE FATTY LIVER PHENOTYPE J. Biol. Chem., September 9, 2005; 280(36): 31686 - 31698. [Abstract] [Full Text] [PDF]

				S. Jitrapakdee, M. Slawik, G. Medina-Gomez, M. Campbell, J. C. Wallace, J. K. Sethi, S. O'Rahilly, and A. J. Vidal-Puig The Peroxisome Proliferator-activated Receptor-{gamma} Regulates Murine Pyruvate Carboxylase Gene Expression in Vivo and in Vitro J. Biol. Chem., July 22, 2005; 280(29): 27466 - 27476. [Abstract] [Full Text] [PDF]

				E. Compe, P. Drane, C. Laurent, K. Diderich, C. Braun, J. H. J. Hoeijmakers, and J.-M. Egly Dysregulation of the Peroxisome Proliferator-Activated Receptor Target Genes by XPD Mutations Mol. Cell. Biol., July 15, 2005; 25(14): 6065 - 6076. [Abstract] [Full Text] [PDF]

				F. Molnar, M. Matilainen, and C. Carlberg Structural Determinants of the Agonist-independent Association of Human Peroxisome Proliferator-activated Receptors with Coactivators J. Biol. Chem., July 15, 2005; 280(28): 26543 - 26556. [Abstract] [Full Text] [PDF]

				S. Vankoningsloo, M. Piens, C. Lecocq, A. Gilson, A. De Pauw, P. Renard, C. Demazy, A. Houbion, M. Raes, and T. Arnould Mitochondrial dysfunction induces triglyceride accumulation in 3T3-L1 cells: role of fatty acid {beta}-oxidation and glucose J. Lipid Res., June 1, 2005; 46(6): 1133 - 1149. [Abstract] [Full Text] [PDF]

				Y. Tu, J. N. Thupari, E.-K. Kim, M. L. Pinn, T. H. Moran, G. V. Ronnett, and F. P. Kuhajda C75 Alters Central and Peripheral Gene Expression to Reduce Food Intake and Increase Energy Expenditure Endocrinology, January 1, 2005; 146(1): 486 - 493. [Abstract] [Full Text] [PDF]

				A. Baldan, J. Relat, P. F. Marrero, and D. Haro Functional interaction between peroxisome proliferator-activated receptors-{alpha} and Mef-2C on human carnitine palmitoyltransferase 1{beta} (CPT1{beta}) gene activation Nucleic Acids Res., September 8, 2004; 32(16): 4742 - 4749. [Abstract] [Full Text] [PDF]

				P. Benatti, G. Peluso, R. Nicolai, and M. Calvani Polyunsaturated Fatty Acids: Biochemical, Nutritional and Epigenetic Properties J. Am. Coll. Nutr., August 1, 2004; 23(4): 281 - 302. [Abstract] [Full Text] [PDF]

				C. Blanquart, R. Mansouri, R. Paumelle, J.-C. Fruchart, B. Staels, and C. Glineur The Protein Kinase C Signaling Pathway Regulates a Molecular Switch between Transactivation and Transrepression Activity of the Peroxisome Proliferator-Activated Receptor {alpha} Mol. Endocrinol., August 1, 2004; 18(8): 1906 - 1918. [Abstract] [Full Text] [PDF]

				H. Sell, J. P. Berger, P. Samson, G. Castriota, J. Lalonde, Y. Deshaies, and D. Richard Peroxisome Proliferator-Activated Receptor {gamma} Agonism Increases the Capacity for Sympathetically Mediated Thermogenesis in Lean and ob/ob Mice Endocrinology, August 1, 2004; 145(8): 3925 - 3934. [Abstract] [Full Text] [PDF]

				J. Zhang, D. I. W. Phillips, C. Wang, and C. D. Byrne Human skeletal muscle PPAR{alpha} expression correlates with fat metabolism gene expression but not BMI or insulin sensitivity Am J Physiol Endocrinol Metab, February 1, 2004; 286(2): E168 - E175. [Abstract] [Full Text] [PDF]

				A. Cabrero, M. Jove, A. Planavila, M. Merlos, J. C. Laguna, and M. Vazquez-Carrera Down-Regulation of Acyl-CoA Oxidase Gene Expression in Heart of Troglitazone-Treated Mice through a Mechanism Involving Chicken Ovalbumin Upstream Promoter Transcription Factor II Mol. Pharmacol., September 1, 2003; 64(3): 764 - 772. [Abstract] [Full Text] [PDF]

				T. A. Hopkins, M. C. Sugden, M. J. Holness, R. Kozak, J. R. B. Dyck, and G. D. Lopaschuk Control of cardiac pyruvate dehydrogenase activity in peroxisome proliferator-activated receptor-{alpha} transgenic mice Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H270 - H276. [Abstract] [Full Text] [PDF]

				M. L. Moore, E. A. Park, and J. B. McMillin Upstream Stimulatory Factor Represses the Induction of Carnitine Palmitoyltransferase-Ibeta Expression by PGC-1 J. Biol. Chem., May 2, 2003; 278(19): 17263 - 17268. [Abstract] [Full Text] [PDF]

				N. Yamazaki, Y. Yamanaka, Y. Hashimoto, T. Hiramatsu, Y. Shinohara, and H. Terada The Gene Encoding Muscle-Type Carnitine Palmitoyltransferase I: Comparison of the 5'-Upstream Region of Human and Rodent Genes J. Biochem., April 1, 2003; 133(4): 523 - 532. [Abstract] [Full Text] [PDF]

				J. Rhee, Y. Inoue, J. C. Yoon, P. Puigserver, M. Fan, F. J. Gonzalez, and B. M. Spiegelman Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): Requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis PNAS, April 1, 2003; 100(7): 4012 - 4017. [Abstract] [Full Text] [PDF]

				G. Chinetti, S. Lestavel, J.-C. Fruchart, V. Clavey, and B. Staels Peroxisome Proliferator-Activated Receptor {alpha} Reduces Cholesterol Esterification in Macrophages Circ. Res., February 7, 2003; 92(2): 212 - 217. [Abstract] [Full Text] [PDF]

				D. Cameron-Smith, L. M Burke, D. J Angus, R. J Tunstall, G. R Cox, A. Bonen, J. A Hawley, and M. Hargreaves A short-term, high-fat diet up-regulates lipid metabolism and gene expression in human skeletal muscle Am. J. Clinical Nutrition, February 1, 2003; 77(2): 313 - 318. [Abstract] [Full Text] [PDF]

				A. Cabrero, M. Merlos, J. C. Laguna, and M. V. Carrera Down-regulation of acyl-CoA oxidase gene expression and increased NF-{kappa}B activity in etomoxir-induced cardiac hypertrophy J. Lipid Res., February 1, 2003; 44(2): 388 - 398. [Abstract] [Full Text] [PDF]

				J. A. Kramer, J. LeDeaux, D. Butteiger, T. Young, C. Crankshaw, H. Harlow, L. Kier, and B. G. Bhat Transcription Profiling in Rat Liver in Response to Dietary Docosahexaenoic Acid Implicates Stearoyl-Coenzyme A Desaturase as a Nutritional Target for Lipid Lowering J. Nutr., January 1, 2003; 133(1): 57 - 66. [Abstract] [Full Text] [PDF]

				J. G. Menke, K. L. Macnaul, N. S. Hayes, J. Baffic, Y.-S. Chao, A. Elbrecht, L. J. Kelly, M.-H. Lam, A. Schmidt, S. Sahoo, et al. A Novel Liver X Receptor Agonist Establishes Species Differences in the Regulation of Cholesterol 7{alpha}-Hydroxylase (CYP7a) Endocrinology, July 1, 2002; 143(7): 2548 - 2558. [Abstract] [Full Text] [PDF]

				O. Barbier, I. P. Torra, Y. Duguay, C. Blanquart, J.-C. Fruchart, C. Glineur, and B. Staels Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., May 1, 2002; 22(5): 717 - 726. [Abstract] [Full Text] [PDF]

				F. M. Campbell, R. Kozak, A. Wagner, J. Y. Altarejos, J. R. B. Dyck, D. D. Belke, D. L. Severson, D. P. Kelly, and G. D. Lopaschuk A Role for Peroxisome Proliferator-activated Receptor alpha (PPARalpha ) in the Control of Cardiac Malonyl-CoA Levels. REDUCED FATTY ACID OXIDATION RATES AND INCREASED GLUCOSE OXIDATION RATES IN THE HEARTS OF MICE LACKING PPARalpha ARE ASSOCIATED WITH HIGHER CONCENTRATIONS OF MALONYL-CoA AND REDUCED EXPRESSION OF MALONYL-CoA DECARBOXYLASE J. Biol. Chem., February 1, 2002; 277(6): 4098 - 4103. [Abstract] [Full Text] [PDF]

				H. S. Ahuja, S. Liu, D. L. Crombie, M. Boehm, M. D. Leibowitz, R. A. Heyman, C. Depre, L. Nagy, P. Tontonoz, and P. J. A. Davies Differential Effects of Rexinoids and Thiazolidinediones on Metabolic Gene Expression in Diabetic Rodents Mol. Pharmacol., April 1, 2001; 59(4): 765 - 773. [Abstract] [Full Text]

				A. Minnich, N. Tian, L. Byan, and G. Bilder A potent PPAR{alpha} agonist stimulates mitochondrial fatty acid {beta}-oxidation in liver and skeletal muscle Am J Physiol Endocrinol Metab, February 1, 2001; 280(2): E270 - E279. [Abstract] [Full Text] [PDF]

				N. M. Lapsys, A. D. Kriketos, M. Lim-Fraser, A. M. Poynten, A. Lowy, S. M. Furler, D. J. Chisholm, and G. J. Cooney Expression of Genes Involved in Lipid Metabolism Correlate with Peroxisome Proliferator-Activated Receptor {gamma} Expression in Human Skeletal Muscle J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4293 - 4297. [Abstract] [Full Text]

				R. B. Vega, J. M. Huss, and D. P. Kelly The Coactivator PGC-1 Cooperates with Peroxisome Proliferator-Activated Receptor alpha in Transcriptional Control of Nuclear Genes Encoding Mitochondrial Fatty Acid Oxidation Enzymes Mol. Cell. Biol., March 1, 2000; 20(5): 1868 - 1876. [Abstract] [Full Text]

				K. A. J. M. VAN DER LEE, P. H. M. WILLEMSEN, G. J. VAN DER VUSSE, and M. VAN BILSEN Effects of fatty acids on uncoupling protein-2 expression in the rat heart FASEB J, March 1, 2000; 14(3): 495 - 502. [Abstract] [Full Text]

				G. Woldegiorgis, J. Shi, H. Zhu, and D. N. Arvidson Functional Characterization of Mammalian Mitochondrial Carnitine Palmitoyltransferases I and II Expressed in the Yeast Pichia pastoris J. Nutr., February 1, 2000; 130(2): 310 - 310. [Abstract] [Full Text]

				K. A. J. M. van der Lee, M. M. Vork, J. E. De Vries, P. H. M. Willemsen, J. F. C. Glatz, R. S. Reneman, G. J. Van der Vusse, and M. Van Bilsen Long-chain fatty acid-induced changes in gene expression in neonatal cardiac myocytes J. Lipid Res., January 1, 2000; 41(1): 41 - 47. [Abstract] [Full Text]

				S. D Clarke, P. Thuillier, R. A Baillie, and X. Sha Peroxisome proliferator-activated receptors: a family of lipid-activated transcription factors Am. J. Clinical Nutrition, October 1, 1999; 70(4): 566 - 571. [Abstract] [Full Text] [PDF]

				B. Desvergne and W. Wahli Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism Endocr. Rev., October 1, 1999; 20(5): 649 - 688. [Abstract] [Full Text]

				V. Giguère Orphan Nuclear Receptors: From Gene to Function Endocr. Rev., October 1, 1999; 20(5): 689 - 725. [Abstract] [Full Text]

				T. C. Leone, C. J. Weinheimer, and D. P. Kelly A critical role for the peroxisome proliferator-activated receptor alpha  (PPARalpha ) in the cellular fasting response: The PPARalpha -null mouse as a model of fatty acid oxidation disorders PNAS, June 22, 1999; 96(13): 7473 - 7478. [Abstract] [Full Text] [PDF]

				Y.-T. Zhou, Z.-W. Wang, M. Higa, C. B. Newgard, and R. H. Unger Reversing adipocyte differentiation: Implications for treatment of obesity PNAS, March 2, 1999; 96(5): 2391 - 2395. [Abstract] [Full Text] [PDF]

				P. Gervois, S. Chopin-Delannoy, A. Fadel, G. Dubois, V. Kosykh, J.-C. Fruchart, J. Najïb, V. Laudet, and B. Staels Fibrates Increase Human REV-ERB{alpha} Expression in Liver via a Novel Peroxisome Proliferator-Activated Receptor Response Element Mol. Endocrinol., March 1, 1999; 13(3): 400 - 409. [Abstract] [Full Text]

				R. C. Cooksey, L. F. Hebert Jr., J.-H. Zhu, P. Wofford, W. T. Garvey, and D. A. McClain Mechanism of Hexosamine-Induced Insulin Resistance in Transgenic Mice Overexpressing Glutamine:Fructose-6-Phosphate Amidotransferase: Decreased Glucose Transporter GLUT4 Translocation and Reversal by Treatment with Thiazolidinedione Endocrinology, March 1, 1999; 140(3): 1151 - 1157. [Abstract] [Full Text]

				B. I. Frohnert, T. Y. Hui, and D. A. Bernlohr Identification of a Functional Peroxisome Proliferator-responsive Element in the Murine Fatty Acid Transport Protein Gene J. Biol. Chem., February 12, 1999; 274(7): 3970 - 3977. [Abstract] [Full Text] [PDF]

				G.-S. Yu, Y.-C. Lu, and T. Gulick Co-regulation of Tissue-specific Alternative Human Carnitine Palmitoyltransferase Ibeta Gene Promoters by Fatty Acid Enzyme Substrate J. Biol. Chem., December 4, 1998; 273(49): 32901 - 32909. [Abstract] [Full Text] [PDF]

				J. M. Brandt, F. Djouadi, and D. P. Kelly Fatty Acids Activate Transcription of the Muscle Carnitine Palmitoyltransferase I Gene in Cardiac Myocytes via the Peroxisome Proliferator-activated Receptor alpha J. Biol. Chem., September 11, 1998; 273(37): 23786 - 23792. [Abstract] [Full Text] [PDF]

				M.-H. Hsu, U. Savas, K. J. Griffin, and E. F. Johnson Identification of Peroxisome Proliferator-responsive Human Genes by Elevated Expression of the Peroxisome Proliferator-activated Receptor alpha in HepG2 Cells J. Biol. Chem., July 20, 2001; 276(30): 27950 - 27958. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mascaró, C. Articles by Haro, D. Search for Related Content PubMed PubMed Citation Articles by Mascaró, C. Articles by Haro, D. Social Bookmarking                      What's this?